Análisis Argos
RPRX
RPRXBarata · ojo al riesgo1 señal de riesgo
Royalty Pharma plc · Healthcare
US$ 59.97
precio al 2026-07-28
Valor justo Argos*
US$ 70–78
vs. su valor justo
22% por debajo
Score Argos
49/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 3.8% al año — menos de lo que viene demostrando (4%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
✓Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Riesgos
!Venta significativa de insiders en el último trimestre.
!Balance frágil: la deuda pesa sobre el negocio.
!Beneish M-Score sugiere manipulación (24.72)
VALOR4/6FUTURO4/6PASADO3/6SALUD1/6DIVIDENDO5/6
El Iris de calidad
VALOR4/6FUTURO4/6PASADO3/6SALUD1/6DIVIDENDO5/6
ValorCotiza por debajo de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance frágil
DividendoDevuelve capital al accionista
Score Argos49de 100Barata · ojo al riesgo
Ingresos▲5%
US$ 2.4 B
Margen operativo▲15%
65.6%
Flujo de caja libre▼10%
US$ 2.5 B
Deuda neta
US$ 8.3 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 25.8B
P/E33.5x
EV/EBITDA21.8x
FCF yield9.7%
ROIC10.5%
Margen operativo65.6%
Crecim. ingresos+5.1%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 10 jul
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com · 10 jul
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com · 10 jul
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com · 9 jul
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
etftrends.com · 11 jun
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
seekingalpha.com · 9 jun
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
zacks.com · 9 jun
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
seekingalpha.com · 5 jun
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.